Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV)

Trial Profile

Safety and Efficacy With Twice Daily Brinzolamide 1%/Brimonidine 0.2% (SIMBRINZA) as an Adjunctive Therapy to Travoprost 0.004%/Timolol 0.5% (DUOTRAV)

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 11 Aug 2017

At a glance

  • Drugs Brimonidine/brinzolamide (Primary) ; Travoprost/timolol (Primary)
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Sponsors Alcon
  • Most Recent Events

    • 08 May 2017 Planned End Date changed from 28 Aug 2017 to 26 Jan 2019.
    • 08 May 2017 Planned primary completion date changed from 28 Aug 2017 to 26 Jan 2019.
    • 28 Mar 2017 Planned End Date changed from 26 Jan 2019 to 28 Aug 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top